Long-term Registry of Patients Treated With Loncastuximab Tesirine

Status Withdrawn

Clinical Trial Summary

Retrospective and prospective multi-center observational study of patients with B-cell lymphomas treated with loncastuximab tesirine treatment in real-world practice.

Clinical Trial Description

The purpose of this study is to assess treatment patterns and generate evidence on the effectiveness and safety of loncastuximab tesirine treatment in real-world practice. This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05160064
Study type	Observational [Patient Registry]
Source	ADC Therapeutics S.A.
Contact
Status	Withdrawn
Phase
Start date	June 30, 2022
Completion date	January 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02891590` - Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas	Phase 1
Completed	`NCT01068392` - Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL)	Phase 2
Terminated	`NCT01744912` - Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies	Phase 1
Completed	`NCT03218072` - A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell Lymphomas	Phase 1
Completed	`NCT01478269` - Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen	N/A
Recruiting	`NCT02247609` - Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas	Phase 1/Phase 2
Recruiting	`NCT00801216` - High-Dose Sequential Chemoimmunotherapy for B-Cell Lymphomas With Central Nervous System Involvement	Phase 2
Completed	`NCT01613300` - Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients	Phase 2
Active, not recruiting	`NCT05773040` - A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas	Phase 1